Jefferies raised the firm’s price target on Kymera Therapeutics (KYMR) to $122 from $73 and keeps a Buy rating on the shares. Following expectation-beating healthy volunteer data in June, oral STAT6 degrader KT-621 delivered “remarkable” first-in-patient atopic dermatitis results, the analyst tells investors in a research note. The firm added all key measures such as STAT6 degradation, biomarker reduction, and clinical endpoints like EASI-50 are comparable or superior to Dupixent, reinforcing its “oral Dupixent” potential.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics falls -9.2%
- Kymera Therapeutics price target raised to $116 from $80 at Truist
- Kymera Therapeutics’ KT-621: Promising Oral Treatment for Atopic Dermatitis and Asthma Expansion Potential
- Kymera Therapeutics price target raised to $134 from $84 at H.C. Wainwright
- Kymera Therapeutics price target raised to $120 from $67 at Oppenheimer